Skip to main content

Generics

  • NACDS, NCPA claim pharmacy victory after withdrawal of Medicaid program provisions

    ALEXANDRIA, Va. The National Association of Chain Drug Stores and the National Community Pharmacists Association heralded the withdrawal of two provisions from the Medicaid program that would have had retail pharmacies selling generic drugs at a loss.

     

  • IMS Health executive: Generic competition can help U.S. save billions

    NEW YORK Loss of patent protection for branded drugs and subsequent competition from generics could save the U.S. healthcare system $70 billion or more over the next four years, according to published reports.

     

    Reuters reported IMS Health SVP Murray Aitken as saying at the Reuters Health Summit that generics also would increase their dominance in terms of prescriptions dispensed, increasing from 77% during the first half of this year to perhaps 85% by 2014.

     

     

  • Report: Government officials question FDA's approval of generic Lovenox

    NEW YORK Government officials said problems have arisen with the Food and Drug Administration’s approval of a generic blood-thinning drug due to its previous relationship with the generic drug’s manufacturer, according to published reports.

     

  • Merck releases results from phase-3 studies of hepatitis C drug

    BOSTON An investigative treatment for hepatitis C got strong results in patients who had failed previous treatments or who were new to treatment, according to results of a late-stage clinical trial program announced this week.

  • Biogen Idec, Cardiokine terminate lixivaptan agreement

    WESTON, Mass. Swiss drug maker Biogen Idec and U.S. drug maker Cardiokine have terminated an agreement to develop a treatment for abnormally low sodium levels in the blood, the two companies said Wednesday.

     

    The agreement will give Cardiokine all rights to lixivaptan, a treatment for the condition, known as hyponatremia. The collaboration began in 2007, and the drug is in late-stage clinical studies.

     

     

  • Watson's Q3 sales jump 33%

    MORRISTOWN, N.J. Sales for generic drug maker Watson Pharmaceuticals grew 33%, to $882.4 million, in third quarter 2010, according to an earnings report released Thursday.

     

    The sales figure for the current quarter compared with $662.1 million in third quarter 2009. Profits were $105.9 million, compared with $90 million in third quarter 2009.

     

     

    “Watson delivered another quarter of strong financial results and continued progress against our strategic objectives,” Watson president and CEO Paul Bisaro said.

  • Lupin's generic Clarinex gets FDA approval

    SILVER SPRING, Md. The Food and Drug Administration has approved a generic treatment made by Lupin Pharmaceuticals for allergies, according to FDA records.

     

    The drug is a generic version of Schering-Plough’s Clarinex.

     

     

    Clarinex has annual sales of around $229 million, according to IMS Health data reported by several media in India, where Lupin is based.

     

  • BIO, GPhA and Sandoz testify at FDA biosimilars hearing

    SILVER SPRING, Md. The main lobbies for the biotechnology and generic drug industries, and a leading manufacturer of generic drugs, testified Wednesday at a hearing sponsored by the Food and Drug Administration to collect public and industry input on the implementation of the regulatory approval pathway for follow-on biologics included in the healthcare-reform bill.

     

X
This ad will auto-close in 10 seconds